GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
Progress
36% Bias Score
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Progress
40% Bias Score
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Zepbound Shows 47% Greater Weight Loss Than Wegovy in Obesity Trial
A clinical trial showed that adults using the obesity drug Zepbound lost 47% more weight on average than those using Wegovy after 18 months, achieving an average weight loss of 50 pounds compared to 33 pounds, respectively.
Progress
48% Bias Score
GLP-1 Agonists and Alcohol Dependence
GLP-1 agonists show promise in treating alcohol use disorder, but further research is needed to confirm their effectiveness and understand their mechanisms.
GLP-1 Agonists and Alcohol Dependence
GLP-1 agonists show promise in treating alcohol use disorder, but further research is needed to confirm their effectiveness and understand their mechanisms.
Progress
0% Bias Score
BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments
The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.
BBVA Award Recognizes GLP-1 Hormone Discoverers for Diabetes, Obesity Treatments
The BBVA Foundation Frontiers of Knowledge Award in Biomedicine was given to four researchers for their discovery of the GLP-1 hormone's role in glucose regulation, appetite, and its implications for treating type 2 diabetes, obesity, and neurodegenerative diseases.
Progress
32% Bias Score
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Progress
48% Bias Score
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Progress
36% Bias Score